Clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas treated with a risk-based strategy: A report from Children’s Oncology Group study ARST0332

Douglass DP, Coffin CM, Randall RL, Yang Y, Barkauskas DA, Million L, McCarville MB, Pappo AS, Weiss AR, Spunt SL. Clinical features and outcomes of young patients with low-grade non-rhabdomyosarcoma soft tissue sarcomas treated with a risk-based strategy: A report from Children’s Oncology Group study ARST0332. Pediatr Blood Cancer. 2024 Aug;71(8):e31062. doi: 10.1002/pbc.31062. Epub 2024 May 16. PubMed PMID: 38757485; PubMed Central PMCID: PMC11534274.

In retrospective analyses, the Pediatric Oncology Group (POG) and the Federation National des Centres de Lutte Contre le Cancer (FNCLCC) histologic grade predict outcome in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), but prospective data on grading, clinical features and outcomes of low-grade NRSTS are limited. We analyzed patients <30 years of age enrolled on Children’s Oncology Group (COG) study ARST0332(NCT00346164) with POG grade 1 or 2 NRSTS. Low-risk patients were treated with surgery alone. Intermediate-/high-risk patients received ifosfamide/doxorubicin and radiotherapy, with definitive resection either before or after 12 weeks of chemoradiotherapy.